Cargando…

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production...

Descripción completa

Detalles Bibliográficos
Autores principales:	Offersgaard, Anna, Duarte Hernandez, Carlos Rene, Pihl, Anne Finne, Costa, Rui, Venkatesan, Nandini Prabhakar, Lin, Xiangliang, Van Pham, Long, Feng, Shan, Fahnøe, Ulrik, Scheel, Troels Kasper Høyer, Ramirez, Santseharay, Reichl, Udo, Bukh, Jens, Genzel, Yvonne, Gottwein, Judith Margarete
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310283/ https://www.ncbi.nlm.nih.gov/pubmed/34209694 http://dx.doi.org/10.3390/vaccines9070706

Ejemplares similares

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2022)

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
por: Pihl, Anne F., et al.
Publicado: (2018)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
por: Czarnota, Anna, et al.
Publicado: (2020)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
por: Fahnøe, Ulrik, et al.
Publicado: (2022)

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
por: Zhou, Yuyong, et al.
Publicado: (2021)

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
por: Zhou, Yuyong, et al.
Publicado: (2022)

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
por: Lothert, Keven, et al.
Publicado: (2020)

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
por: Offersgaard, Anna, et al.
Publicado: (2023)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
por: Jensen, Sanne Brun, et al.
Publicado: (2019)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production
por: Tapia, Felipe, et al.
Publicado: (2016)

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation
por: Genzel, Yvonne, et al.
Publicado: (2010)

Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the “von Magnus effect”
por: Tapia, Felipe, et al.
Publicado: (2019)

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
por: Ramirez, Santseharay, et al.
Publicado: (2021)

Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles
por: Czarnota, Anna, et al.
Publicado: (2023)

High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system
por: Galli, Andrea, et al.
Publicado: (2021)

Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture
por: Scheel, Troels K. H., et al.
Publicado: (2013)

Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems
por: Scheel, Troels K. H., et al.
Publicado: (2012)

Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors
por: Rhazi, Halima, et al.
Publicado: (2021)

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection
por: Fossat, Nicolas, et al.
Publicado: (2023)

Neutralization and receptor use of infectious culture–derived rat hepacivirus as a model for HCV
por: Wolfisberg, Raphael, et al.
Publicado: (2022)

Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication
por: Galli, Andrea, et al.
Publicado: (2021)

Bioreactor Scalability: Laboratory-Scale Bioreactor Design Influences Performance, Ecology, and Community Physiology in Expanded Granular Sludge Bed Bioreactors
por: Connelly, Stephanie, et al.
Publicado: (2017)

Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production
por: Schulze-Horsel, Josef, et al.
Publicado: (2008)

Effect of influenza virus infection on key metabolic enzyme activities in MDCK cells
por: Janke, Robert, et al.
Publicado: (2011)

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems
por: Tapia, Felipe, et al.
Publicado: (2017)

Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment
por: Pedersen, Martin S., et al.
Publicado: (2021)

Impact of different influenza cultivation conditions on HA N-Glycosylation
por: Roedig, Jana V, et al.
Publicado: (2011)

Cell culture-based production of defective interfering particles for influenza antiviral therapy
por: Wasik, Milena A., et al.
Publicado: (2017)

The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
por: Bayley, Rachel, et al.
Publicado: (2017)

Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors
por: Gallego‐Murillo, Joan Sebastián, et al.
Publicado: (2022)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
por: Underwood, Alexander P., et al.
Publicado: (2021)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production
por: Nikolay, Alexander, et al.
Publicado: (2018)

Impact of Influenza A Virus Infection on Growth and Metabolism of Suspension MDCK Cells Using a Dynamic Model
por: Ramos, João Rodrigues Correia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ursgjcpq45v70iqou83se7upr